INIS
patients
100%
validation
75%
plasma
71%
concentration
57%
drugs
55%
humans
40%
blood
37%
cancer
34%
hplc
30%
range
29%
temperature range 0273-0400 k
25%
edta
22%
doses
21%
liquid column chromatography
21%
wastes
20%
children
20%
storage
20%
accuracy
17%
chromatography
17%
methanol
16%
communities
16%
mass spectrometry
15%
precision
14%
high-performance liquid chromatography
14%
comparative evaluations
14%
detection
13%
stability
13%
data
13%
performance
13%
size
13%
water
13%
sampling
12%
risks
12%
therapy
12%
acetates
11%
spectra
11%
populations
11%
kidneys
11%
lung cells
11%
molecules
10%
interactions
10%
surveys
10%
metastases
10%
mutants
10%
recommendations
10%
carcinomas
10%
particles
10%
gastric acid
10%
tumor necrosis factor
10%
urine
10%
genetics
10%
pneumonia
10%
bone joints
10%
compliance
10%
united kingdom
10%
clinical trials
9%
ionization
9%
mass spectrometers
9%
formic acid
9%
toxicity
9%
freezing
8%
sample preparation
8%
control
7%
interfaces
7%
precipitation
7%
proteins
7%
lead method
7%
diseases
7%
auc
6%
photodiodes
6%
c-reactive protein
6%
mutations
6%
levels
6%
kinases
6%
tyrosine
6%
carbon 18
5%
carbon 20
5%
hiv
5%
clearance
5%
Keyphrases
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
42%
Analytical Method
30%
Liposomal Amphotericin B
30%
Dried Blood Spots
29%
Pharmacokinetics
28%
Clinical Validation
21%
MS Method
21%
Human Plasma
20%
Everolimus
20%
Medication Waste
20%
Osimertinib
20%
Small Molecule Inhibitors
18%
EDTA Plasma
17%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
15%
Pharmacokinetic Study
15%
Room Temperature
15%
Plasma Concentration
13%
Patient Characteristics
13%
Etanercept
12%
Pralsetinib
12%
K2EDTA
12%
Selpercatinib
12%
Lorlatinib
12%
Brigatinib
12%
Storage Conditions
11%
Validation Studies
11%
Methanol
10%
Multiplexing
10%
Gefitinib
10%
Community-acquired Pneumonia in children
10%
Adagrasib
10%
Sotorasib
10%
Pharmacist
10%
Temperature Storage
10%
Particle Formation
10%
Acquired Resistance
10%
UHPLC-DAD
10%
Colorectal Cancer
10%
Acid Suppressant
10%
Ultra-performance Liquid Chromatography
10%
Biosimilar
10%
Attention Deficit Hyperactivity Disorder
10%
Erlotinib
10%
Morbid Obesity
10%
Crizotinib
10%
Community-acquired Pneumonia
10%
Patient Compliance
10%
Oncology Setting
10%
Autism
10%
Tourniquet Use
10%
Fixed Dosing
10%
Amphotericin B
10%
Autism Spectrum Disorder
10%
Drug-drug Interaction Study
10%
Analytical Validation
10%
Storage Recommendations
10%
Drug Storage
10%
Raltegravir
10%
Citalopram
10%
Aggregate Formation
10%
Stability Results
10%
Sunitinib
10%
Psychiatric Comorbidity
10%
International Survey
10%
Overall Survival
10%
Patients with Cancer
10%
Older Patients
10%
Matched Cohort Study
10%
Genetic Polymorphism
10%
Gastric Acid Suppressant
10%
Dried Blood Spot Samples
10%
Mycophenolic Acid
10%
Human Plasma Samples
10%
Critically Ill Patients
10%
Psychotropic Drug Use
10%
Tacrolimus
10%
Ropivacaine
10%
Redispensing
10%
Comparator Group
10%
Medication Factor
10%
Alectinib
10%
Resistance to Targeted Therapy
10%
BRAF mutant
10%
Molecular Landscape
10%
Total Knee Arthroplasty
10%
Nitrofurantoin
10%
United Kingdom
10%
Clear-cell Metastatic Renal Cell Carcinoma
10%
Combination of Therapies
10%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
10%
Tumour Necrosis Factor Inhibitor (TNFi)
10%
Pharmacokinetic Drug Interactions
10%
Obese Men
10%
Chromatographic Separation
9%
Mass Spectrometry Methods
8%
Resistant Cells
7%
BRAF Inhibitor (BRAFi)
7%
Ammonium Acetate
7%
Clinically Significant
7%
Freezing Temperature
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
52%
Amphotericin B
30%
Ultra High Performance Liquid Chromatography
23%
Ethylenediaminetetraacetic Acid
23%
Cohort Study
21%
Everolimus
20%
Brigatinib
20%
Lorlatinib
20%
High Performance Liquid Chromatography
20%
Methanol
16%
Non Small Cell Lung Cancer
16%
Malignant Neoplasm
15%
Community Pharmacy
13%
Clinical Trial
12%
Etanercept
12%
Epidermal Growth Factor Receptor
12%
Acetonitrile
11%
Gefitinib
10%
Psychotropic Agent
10%
Ammonium Formate
10%
Combination Therapy
10%
Community Acquired Pneumonia
10%
Tumor Necrosis Factor Inhibitor
10%
Erlotinib
10%
Crizotinib
10%
Biosimilar Agent
10%
Drug-Drug Interaction
10%
Prescription Drug
10%
Raltegravir
10%
Citalopram
10%
Autism
10%
Tacrolimus
10%
Mycophenolic Acid
10%
Osimertinib
10%
Nitrofurantoin
10%
Ropivacaine
10%
Alectinib
10%
Attention Deficit Disorder
10%
Connective Tissue Cancer
10%
Comorbidity
10%
Colorectal Carcinoma
10%
Cross-Sectional Study
8%
Drug Resistance
6%
Pharmacotherapy
6%
Electrospray Ionization
5%
Formate
5%
Ammonium Acetate
5%
C Reactive Protein
5%
Hyperbarism
5%
Prospective Study
5%
Nanoparticle
5%
Light Scattering
5%